All In Biotech

Drug Trial Radar · NCT02590432

An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation

An Open-label, Long-term Study to Assess the Immunogenicity of Linaclotide Administered Orally to Adult Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation.

Last checked: Nov 19, 2026Latest source record: Aug 22, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 828 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

828

Actual

Start

Nov 1, 2015

Primary completion

Feb 5, 2018

Study completion Feb 5, 2018

Sponsor

Lead sponsor
Forest LaboratoriesAbbVie (ABBV)
Sponsor type
Industry
Collaborators
Ironwood Pharmaceuticals, Inc.
First posted
Oct 29, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to assess the potential of LINZESS® (linaclotide) treatment to induce the development of anti-drug antibodies (ADAs). The secondary objectives are to provide additional evidence supporting the long-term safety and efficacy of linaclotide in adult irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) participants and to evaluate lower doses of linaclotide.

Conditions

  • Irritable Bowel Syndrome With Constipation
  • Chronic Idiopathic Constipation

Interventions

  • LinaclotideDrug

    Linaclotide capsules, orally, once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Positive Treatment-Related Anti-Drug Antibodies (ADA) in SerumTime frame: Baseline (Day 1) up to 52 weeks or 8 months post last dose if ADA positive at Week 52 (approximately 84 weeks)

Locations

79 sites in 1 country. Site status is shown where the registry gives one.

  • Pinnacle Research Group, LLC

    Anniston, Alabama

  • North Alabama Research Center, LLC

    Athens, Alabama

  • Alliance Clinical Research

    Childersburg, Alabama

  • G & L Research, LLC

    Foley, Alabama

  • Radiant Research, Inc.

    Chandler, Arizona

  • Radiant Research, Inc.

    Scottsdale, Arizona

  • Clinical Research Institute of Arizona, LLC

    Surprise, Arizona

  • Clinical Research Consortium

    Tempe, Arizona

  • Desert Sun Clinical Research, LLC.

    Tucson, Arizona

  • Preferred Research Partners, Inc.

    Little Rock, Arkansas

  • Applied Research Center of Arkansas

    Little Rock, Arkansas

  • Kindred Medical Institute for Clinical Trials, LLC

    Corona, California

  • Global Clinical Trials LLC

    Costa Mesa, California

  • Diagnamics Inc

    Encinitas, California

  • MD Studies, Inc.

    Fountain Valley, California

  • Research Center of Fresno, Inc.

    Fresno, California

  • VVCRD Clinical Research

    Garden Grove, California

  • Facey Medical Foundation

    Mission Hills, California

  • Clinical Trials Research

    Sacramento, California

  • Northern California Research

    Sacramento, California

  • Artemis Institute for Clinical Research

    San Diego, California

  • Precision Research Institute

    San Diego, California

  • Empire Clinical Research

    Upland, California

  • Lynn Institute of Denver

    Denver, Colorado

  • ZASA Clinical Research

    Boynton Beach, Florida

  • Meridien Research

    Bradenton, Florida

  • Clinical Research of Brandon LLC

    Brandon, Florida

  • Clinical Physiology Associates

    Fort Myers, Florida

  • Direct Helpers Research Center

    Hialeah, Florida

  • Eastern Research, Inc.

    Hialeah, Florida

  • Center for Advanced Gastroenterology

    Maitland, Florida

  • Florida Medical Center and Research, Inc.

    Miami, Florida

  • Clinical Neuroscience Solutions, Inc

    Orlando, Florida

  • Accord Clinical Research

    Port Orange, Florida

  • Meridien Research

    St. Petersburg, Florida

  • River Birch Research Alliance, LLC

    Blue Ridge, Georgia

  • North Georgia Clinical Research

    Woodstock, Georgia

  • Northwest Clinical Trials

    Boise, Idaho

  • Rockford Gastroenterology Associates

    Rockford, Illinois

  • Iowa Digestive Center, PC

    Clive, Iowa

Showing 40 of 79 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.